FDA Clearance Tracker · P950021-S014
ADVIA CENTAUR PSA ASSAY
Last checked: Nov 20, 2026Latest source record: Jul 27, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Jul 27, 2017
Approved
Time to decision
812 days
Received May 7, 2015. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P950021-S014
- Device name
- ADVIA CENTAUR PSA ASSAY
- Applicant
- Siemens Healthcare Diagnostics
- Applicant location
- East Walpole, MA
- Received
- May 7, 2015
- Decided
- Jul 27, 2017
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P950021
Device type
- Device type
- Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer (MTF)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for the migration of the ADVIA Centaur PSA assay to the ADVIA Centaur XPT system
Source documents
Other decisions for Siemens Healthcare Diagnostics
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260674 · Decided Nov 6, 2026 · 249 days after receipt
Device type: System, Test, Vitamin D (MRG) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.